Fieldview Capital Management LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Fieldview Capital Management LLC bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 15,291 shares of the company’s stock, valued at approximately $1,716,000.

Other large investors have also modified their holdings of the company. Whittier Trust Co. of Nevada Inc. raised its stake in shares of TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in TransMedics Group in the 3rd quarter valued at $28,000. Optiver Holding B.V. grew its position in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after buying an additional 191 shares during the last quarter. LOM Asset Management Ltd acquired a new position in TransMedics Group in the 3rd quarter valued at $34,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in TransMedics Group during the 2nd quarter worth $48,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity at TransMedics Group

In other news, Director David Weill sold 3,571 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $146.82, for a total value of $524,294.22. Following the completion of the transaction, the director directly owned 12,134 shares of the company’s stock, valued at $1,781,513.88. The trade was a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Nicholas Corcoran sold 2,966 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the completion of the transaction, the insider directly owned 29,831 shares of the company’s stock, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,205 shares of company stock valued at $2,353,002 in the last ninety days. 7.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TMDX. Stifel Nicolaus raised their target price on shares of TransMedics Group from $115.00 to $130.00 and gave the stock a “hold” rating in a research note on Monday. JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Morgan Stanley increased their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Piper Sandler lifted their price objective on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.33.

TransMedics Group Trading Up 4.0%

Shares of TransMedics Group stock opened at $134.77 on Tuesday. TransMedics Group, Inc. has a 1 year low of $62.23 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The business has a 50 day moving average price of $135.58 and a 200 day moving average price of $127.08. The company has a market capitalization of $4.62 billion, a P/E ratio of 27.50 and a beta of 1.98.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.